NEW YORK — Swedish diagnostics firm Immunovia said on Tuesday that its US subsidiary has received clinical laboratory licensure from the Rhode Island Department of Health for its Immray PanCan-d blood test for the early detection of pancreatic cancer.
"Receiving licensure in Rhode Island now allows us to offer Immray PanCan-d in 46 states," Jeff Borcherding, CEO of the US subsidiary, said in a statement. "We expect additional state licensures to follow."
Immray PanCan-d is a microarray-based test designed to detect nine serum biomarkers of pancreatic ductal adenocarcinoma, including the protein CA19-9, which are analyzed using a proprietary algorithm to generate a cancer risk classification.
The test was launched in the US last summer after it received final approval from the Massachusetts Department of Public Health.